Novel CDKs inhibitors for the treatment of solid tumour by simultaneously regulating the cell cycle and transcription control

Xin Wanga,*, Kaiyuan Denga,*, Cheng Wanga, Yaoli, Tianqi Wanga, Zhi Huanga, Yakun Maa, Peiqing Suna,e, Yishi,b, Shengyong Yangd, Yan Fana,b and Rong Xianga,b,c

aDepartment of Medicinal Chemistry, School of Medicine, Nankai University, Tianjin, China; b2011 Project Collaborative Innovation Center for Biotherapy of Ministry of Education, Tianjin, China; cState Key Laboratory of Medicinal Chemical Biology, Tianjin, China; dDepartment of Medical Oncology, Cancer Center, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, China; eDepartment of Cancer Biology, Wake Forest Comprehensive Cancer Center, Wake Forest School of Medicine, Winston-Salem, NC, USA

ABSTRACT
A novel series of cyclin-dependent kinases (CDKs) inhibitors, which play critical roles in the cell cycle control and regulation of cell transcription, were synthesised. A systematic study of enzymatic and cellular assays led to the identification of compound X22 with a nanomolar potency against CDK4 and CDK9 and potent antiproliferative activities against a panel of tumour cell lines. X22 could induce cell cycle arrest and cell apoptosis in cancer cell lines. X22 dose-dependently inhibits signalling pathways downstream of CDKs in cancer cells. In vivo antitumor activity assays, oral administration of X22 led to significant tumour regression in mouse model without obvious toxicity. Superior anti-cancer efficacy in vitro and in vivo of X22 demonstrated combined depletion of cell cycle and transcriptional CDK all contributed to antitumor activity. Taken together, concomitant inhibition of cell cycle and transcriptional CDK activities provided valuable guide for further structural optimisation.

1. Introduction
Cancer is a multigenetic disease with the hallmark that multiple signalling pathways aberration, which often require multiple therapeutics interventions.1,2. Kinases mediate various cellular activities due to their critical roles in cellular signalling, such as proliferation, apoptosis, transcription, differentiation and so on.3,4 which have been demonstrated as promising drug targets for the treatment of many diseases such as cancers5–7. Kinase inhibitors are widely employed in clinical oncology.8,9. Simultaneous inhibition of different mechanisms using multi-kinase inhibitors could yield superior efficacy, such as synergy effects, avoiding drug resistance and so on.10

Out of numerous kinases, cyclin-dependent kinases (CDKs) are protein kinases involved in important cellular processes due to the complexity of their roles. They regulate the cell division, apoptosis, transcription and differentiation, which involved in a number of pathological conditions such as cancer.11,12. CDKs are divided into two groups based on their roles in cell cycle progression and transcription regulation.13,14. The first group including CDK subtypes 1, 2, 4 and 6 mainly is involved in cell cycle and the second group including CDK subtypes 7, 8 and 9 are associated with transcription control.11. CDK4/6 binding to cyclin D forming CDK4/6-cyclin D complex, is an important component of cell cycle activation and mediates the transition from G1 to S phase, where cells grow and synthesise proteins in preparation for DNA synthesis.15. Among the transcriptional CDKs, CDK9 has attracted major interest of many groups. CDK9 forming heterodimeric complex with subunit cyclin T or cyclin K phosphorylates the COOH-terminal domain (CTD) of RNA polymerase II (RNAPII) to control the transcription progression.16. As a component of a larger protein complex called positive transcription elongation factor b (P-TEFb), CDK9 stimulate transcription elongation of most protein coding genes17. Phosphorylation of RNAPII is regarded as a marker involved in a variety of human pathological conditions, such as cancer. Inhibition of CDK9 results in reduced levels of antiapoptotic proteins of cancer.18,19.

Dysregulation of CDKs-cyclin pathway resulting in uncontrolled proliferation have been observed in various cancers20–22. Owing to the important role of CDKs in the control of cell division, numerous drugs targeting CDKs were designed and reported in the clinic.23. Several selective CDK4/6 inhibitors have been reported in the recent years. Pfizer’s palbociclib represents the first CDK inhibitor approved by the US FDA in February 2015 to treat HR+/HER2-breast cancer.24,25. Novartis’ ribociclib and Lilly’s abemaciclib also got a fast approval by FDA in March 2017 and September 2017, respectively, to treat HR+/HER2-breast cancer.26,27. While as reported, both palbociclib and ribociclib as selective CDK4/6 inhibitors need to combine with letrozole for the treatment of breast cancer.28,29. Abemaciclib with additional kinase activities, such as CDK1, CDK2 and CDK9 shows unique single-agent activities.30,31. The studies indicate that monotherapy targeting of individual cell cycle CDKs may be insufficient for cancer therapy.
Simultaneous regulating the cell cycle and transcription control could provide superior anticancer efficacy23–34. In an effort to discover novel CDKs inhibitors with high inhibition potency against both cell cycle and transcriptional CDKs, we recently started a medicinal chemistry study based on ribociclib, a latest and selective CDK4 inhibitor and performed a rational drug design. According to the researches, many sulphur atom-containing compounds have immense importance in medicinal chemistry and exhibit anticancer activity35. Moreover, isothiocyanate plays a prominent role in the field of pharmaceuticals with anticancer effects in various cancer types36. Sulphur atom or isothiocyanate-containing derivatives are biologically active agents for drugs used for the treatment of cancer. We reasoned to introduce sulphur atom and isothiocyanate moiety based on pyrrolo-[2,3-d] pyrimidines-2-amine skeleton to proceed structural optimisation on R, L and linker regions (Supplementary Figure S1). In our study, we synthesised a series of novel compounds simultaneously mediating the cell cycle and transcription control of CDKs with high potent inhibition against solid tumour. Compound X22 targeting CDK4 and CDK9 was discovered and exhibited potent antitumor efficacy in vitro and in vivo.

2. Materials and methods

2.1. General methods for chemistry

The commercially obtained chemicals were used directly without further purification. Solvents were purified and distilled following the standard procedures. All the reactions were monitored by thin-layer chromatography (TLC). The NMR spectra were taken on a Bruker AV-400 MHz spectrometer (400 MHz for 1H and 101 MHz for 13C) and chemical shifts were expressed in ppm downfield using tetramethylsilane as the internal standard. High-resolution mass spectra (HRMS) were performed on a VG ZAB-HS mass spectrometer using electron spray ionisation (ESI). All the derivatives for testing bioactivity were purified to >95% purity which was determined by HPLC analysis on a Shimadzu Prominance-i LC-2030C 3D system (column, InertSustain C18, 4.6 x 250 mm, 5 µM; mobile phase, gradient elution of methanol/H2O (90:10); low rate, 1.0 ml/min; UV wavelength, 190 – 800 nm; temperature, 40°C; injection volume, 10 µL). The detailed synthesis of compounds is presented in Supplementary Material.

2.2. Molecular docking

Docking studies were finished by Discovery Studio 3.1 to explore the predicted binding modes of compound X22 in CDK4, CDK6 (PDB code: 4EZ5) and CDK9 (PDB code: 4BCF) respectively. Hydrogen atoms were added by Gold (version 5.0). The images were created by PyMOL.

2.3. Cell lines and cell culture

All the human cancer cell lines were obtained from ATCC. Cells were cultured in RPMI-1640 (Biolnd) medium according to the instructions from ATCC, with the medium containing 10% FBS (Biolnd), 1% antibiotics (penicillin and streptomycin) at 37°C in an atmosphere of 5% CO2.

2.4. Kinase inhibition assays

Kinase inhibition profiles were determined using KinaseProfiler services provided by Eurofins, and ATP concentrations used the Km of corresponding kinases.

2.5. Cytotoxicity assay

Cytotoxicity assay were conducted as described previously using a Cell Counting Kit-8 (CCK-8) assay (#CK04, Dojindo, Kumamoto, Japan)37.

2.6. Cell cycle assay

Cells were plated on six-well culture plates at a density of 5 x 10^5 cells/mL and were treated with the indicated concentrations of X22 or ribociclib for 12, 24, 36 or 48 h after they adheren. Cells were harvested and washed with phosphate buffered saline (PBS) for three times and then fixed with ice cold 75% ethanol overnight. The fixed cells were then washed with PBS and stained with propidium iodide (50 mg/mL) in the presence of RNase A (0.5 mg) for 30 min at 37°C. The stained cells were then subjected to flow cytometry (Modfit, BD) for cell cycle analysis.

2.7. Annexin V-FITC/PI apoptosis assay

Cells at a density of 3 x 10^5 cells/mL were seeded in six-well plates and treated with compounds at different concentrations for 48 h. The cells were then harvested and washed twice with cold PBS. Then the cells were subjected to an Annexin V/PI Apoptosis Detection kit (BD Biosciences) for staining according to manufacturer’s instructions, and finally analysed by flow cytometry (Modfit, BD).

2.8. Western blotting

Protein extraction and western blotting methods were performed as described previously37. The antibodies used in this study including anti-β-actin (Santa Cruz; sc-47778), anti-p53 (CST; #9282), anti-phospho-p53Ser15 (CST; #9284), anti-Bax (CST; #2772), anti-Bcl-2 (BD; #51-6511GR), anti-Rb (CST; #9309), anti-phospho-RbSer807/811 (CST; #8516), anti-phospho-RbSer780 (CST; #9307), anti-RNA polymerase II CTD (Abcam; ab817), anti-RNA polymerase II CTDphospho S5 (Abcam; ab5131), anti-RNA polymerase II CTDphospho S2 (Abcam; ab5095).

2.9. In vivo assay

The experimental procedures of the animal study were proved by the Animal Care and Use Committee at Nankai University. 4T1 breast cancer cells (5 x 10^5) were injected in the mammary fat pads of 6–8 weeks old female BALB/c mice. Once the tumours grew to a volume of approximately 100–150 mm^3, they were placed into five treatment groups (n = 3, with a total tumour number of 15). The mice were treated daily for 18 days via oral gavage. Body weights and tumour size were determined every other day. Tumour measurements were found using a digital vernier calliper, and the volumes were determined using the following calculation: (short^3) x long x 0.5. Experiments were performed under an approved IACUC protocol according to federal and institutional guidelines and regulations. Inhibition rate of tumour growth was calculated using the following formula: 100 x (1 – [tumour...
volume_{final} / C_{0} / tumour volume_{initial} for X22-treated group) / [(tumour volume_{final} / C_{0} / tumour volume_{initial}) for the vehicle-treated group].

2.10. Statistical analysis

Statistical analysis results were analysed values by GraphPad Prism version 6.0 software. For Student t test and ANOVA, \( p < 0.05 \) was considered statistically significant. Values were expressed as means±SEM. Significance was determined by \( \chi^2 \) test, others were determined by Student’s t-test. A value of \( p < 0.05 \) was used as the criterion for statistical significance. ** indicates significant difference with \( p < 0.001 \), * indicates \( p < 0.01 \), and * indicates \( p < 0.05 \).

3. Results and discussion

In our previous study, we found structural optimisation based on the pyrrolo-[2,3-d] pyrimidines-2-amine scaffold could improve the inhibitory activity against the cancer cell cycle as targeting CDK4/6 and transcription as targeting CDK9. As the noteworthy antitumor functions of sulphur atom and isothiocyanate as mentioned above, we introduced these moieties to form molecules to investigate the structure–activity relationship. We changed the substituent at \( R \) position on the phenyl ring, as well as the functional group \( L \) and length of spacer between the isothiocyanato and phenyl ring. The pathways adopted for the synthesis of compounds X1–X23 were carried out as shown in Schemes 1–3. The synthesis of the key intermediates 5a–5e was depicted in Scheme 1. Firstly, refluxing the commercial obtained potassium

Scheme 1. Synthesis of intermediates 5a–5e. **Reagents and conditions: (A) Acetone, 70 °C, overnight; (B) Potassium thioacetate (3.0 eq), THF, 75 °C, 5 h; (C) concentrated HCl, MeOH, 60 °C, 4 h.

Scheme 2. Synthesis of intermediates 17a–18e, 19a–20e. **Reagents and conditions: (A) K2CO3 (2.0 eq), DMF, rt, 4.5 h; (B) m-CPBA (4.5 eq), DCM, 0 °C to rt, 2 h; (C) Fe/AcOH, MeOH, 60 °C, 5 h; (D) Zn, MeOH, rt, 1.5 h; (E) Pd(OAc)2 (0.10 eq), BINAP (0.06 eq), Cs2CO3 (2.0 eq), 1,4-dioxane, 105 °C, 7 h.
Scheme 3. Synthesis of derivatives X1–X23. Reagents and conditions: (A) Hydrazine hydrate (6.0 eq), MeOH, rt, 3 h; (B) CS₂ (20.0 eq), dicyclohexylcarbodiimide (DCC, 1.1 eq), THF, rt; overnight; (C) m-CPBA (1.5 eq), DCM, −10 °C to 0 °C, 2 h; (D) m-CPBA (4.5 eq), DCM, 0 °C to rt, 2 h.

phthalimide 1 with various dibromoalkane in acetone yielded the mono-bromides 3a–3e bearing the phthalimide tail meeting the different length for SAR. Then, 3a–3e were refluxed with potassium thioacetate (KSAc) in THF to afford thioacetates 4a–4e, following acidic hydrolysis reaction in methanol to deprotect, following reacting with carbonates described above underwent Buchwald purification.

were produced via two successive steps without intermediate. In Scheme 2, prepared 5a–5e were aryalted by p-fluoroniobenzene with various R substituents (6a–6d) to give the intermediates 7a–7h. On the other hand, 5a–5e reacted with 1-(bromomethyl)-4-nitrobenzene (X1) to afford the isothiocyanato derivatives 8a–8e. In the example of compound 8a, the isothiocyanato tail was confirmed to be superior than the sulphone, that was also be confirmed in the example of compound 8a versus 7a in Table 1. Further, the derivatives bearing oxidation state of sulphur were tested the IC₅₀ value against CDK4 and CDK9 due to the high inhibition at 1 micromolar concentration (Table 2).

Compared with ribociclib, X7 exhibited excellent potency against CDK4/9 (IC₅₀: 7 and 26 nM, respectively). At the same time, a derivative (X8) with different space between isothiocyanato and phenyl ring was synthesised to determine the changing the activity produced by the length of the tail. The results indicated that the length of the tail could cause changing on the enzymatic inhibitory activity, but still need to be explored the rules of the changing in detail.

Based on preliminary research, we then adopted the H at R position to design several derivatives (X9–X13, Table 1) to focus on the effect of the sulphur and its oxidation state at L position and length of the tail on the enzyme test. Obviously, X9 with sulphone enhanced the inhibition against the three kinases, compared with X8. In the example of compound X9–X13, the inhibition against CDK9 was keeping at a relative high level, but the efficacy activity on CDK4/6 was declined with the increasing space between the isothiocyanato and sulphone structurally.

In view of the importance of the L position and the length of the tail, we attempt to insert a methylene between the L position and the phenyl leading to derivatives X14–X23 (Table 1). Excitingly, X19–X23 were proved high inhibition on all three kinases as well as no obvious difference for the enzymatic activity but X23. We summarised the structure–activity relationships as shown in Supplementary Figure S2.

Since our goal here is to discover CDKs inhibitors with cell cycle arrest and transcription blockade activities having high potency for cancer treatment, we screened compounds exhibiting better kinase inhibitory to do the cytotoxicity assays. The selected compounds, including X7, X19, X20 and X22 were carried out using standard CCK8 assay and the results are shown in Table 3.
Table 1. Structure and enzymatic inhibition activity evaluation of compounds X1–X23.\(^a\)

| Compds. | Structure | Inhibition (%) at 1 \(\mu\)M |
|---------|-----------|-------------------------------|
| Ribociclib | – | – |
| X1 | I H S 3 | 101 ± 0 |
| X2 | I CH\(_3\) S 3 | 35 ± 0.5 |
| X7 | I H SO\(_2\) 3 | 70 ± 2.4 |
| X8 | I H S 1 | 95 ± 0 |
| X9 | I H SO\(_2\) 1 | 83 ± 0.8 |
| X10 | I H SO\(_2\) 2 | 83 ± 0.8 |
| X11 | I H SO\(_2\) 3 | 95 ± 0 |
| X12 | I H SO\(_2\) 4 | 95 ± 0 |
| X13 | I H SO\(_2\) 5 | 95 ± 0 |
| X14 | II H S 2 | 83 ± 0.8 |
| X15 | II H S 3 | 71 ± 0.8 |
| X16 | II H S 4 | 71 ± 0.8 |
| X17 | II H S 5 | 71 ± 0.8 |
| X18 | II H SO\(_2\) 1 | 98 ± 0 |
| X19 | II H SO\(_2\) 2 | 99 ± 0.4 |
| X20 | II H SO\(_2\) 3 | 98 ± 0.4 |
| X21 | II H SO\(_2\) 4 | 97 ± 0.4 |
| X22 | II H SO\(_2\) 5 | 95 ± 0.5 |
| X23 | II H SO\(_2\) 5 | 95 ± 0.5 |

\(^a\)Inhibition activities were determined using the KinaseProfiler of Eurofins. The data represent the mean values of two independent experiments.

Table 2. Enzymatic inhibition activity evaluation of selected compounds.\(^a\)

| Compds. | \(\text{IC}_{50}\) (nM) |
|---------|------------------|
| Ribociclib | 13 ± 1.3 |
| X5 | 331 ± 33.3 |
| X7 | 26 ± 1.1 |
| X8 | – |
| X9 | 43 ± 2.6 |
| X10 | 90 ± 10.5 |
| X11 | – |
| X12 | – |
| X13 | – |
| X14 | 70 ± 2.4 |

\(^a\)The \(\text{IC}_{50}\) values are shown in the forms. The cytotoxic effect of compounds was assayed using CCK-8 assay with 72 h incubation. Data are from three independent experiments.

Table 3. In vitro cell growth inhibition (\(\text{IC}_{50}\)) of selected compounds against multiple cancer cell lines.\(^a\)

| Cell lines | 4T1 | T-47D | MCF7 | A549 | H460 | H1299 |
|------------|-----|-------|------|------|------|-------|
| Ribociclib | 10  | –     | 10   | 10   | 10   | 10    |
| X8 | 1.46 ± 0.34 | 0.41 ± 0.10 | 1.33 ± 0.15 | 3.07 ± 0.11 | 3.22 ± 0.22 | 3.79 ± 0.07 |
| X12 | 0.46 ± 0.07 | 0.16 ± 0.02 | 0.57 ± 0.24 | 1.57 ± 0.07 | 2.79 ± 0.32 | 1.31 ± 0.06 |
| X7 | 0.41 ± 0.10 | 0.10 ± 0.02 | 0.23 ± 0.04 | 0.67 ± 0.03 | 0.92 ± 0.15 | 1.15 ± 0.10 |
| X19 | 0.69 ± 0.14 | 0.72 ± 0.03 | 0.16 ± 0.06 | 1.46 ± 0.28 | 1.45 ± 0.10 | 0.60 ± 0.04 |
| X20 | 0.26 ± 0.19 | 0.12 ± 0.01 | 0.12 ± 0.07 | 0.38 ± 0.02 | 1.50 ± 0.39 | 0.60 ± 0.24 |
| X22 | 0.083 ± 0.34 | 0.11 ± 0.01 | 0.11 ± 0.07 | 0.21 ± 0.07 | 1.80 ± 0.34 | 0.57 ± 0.07 |

\(^a\)The \(\text{IC}_{50}\) values are shown in the forms. The cytotoxic effect of compounds was assayed using CCK-8 assay with 72 h incubation. Data are from three independent experiments.
X8 and X12 with selective CDK9 inhibition and ribociclib as CDK4 inhibitor were assess the cancer cell inhibition assays as control. IC50 values were detected on compounds against breast cancer cell lines (4T1, T47D and MCF7) and lung cancer cell lines (A549, H1299 and H460). The best tumour cell potency of these analogues was obtained for molecule X22, which was also rational inhibitor of CDK9 with IC50 value of 10 nM and CDK4 with IC50 value of 30 nM. The CDK4 inhibitor ribociclib alone was not potent in these solid tumour cells. X22 displayed higher inhibition potency than selective CDK4 inhibitor ribociclib and selective CDK9 inhibitor X8 and X12. This result demonstrated that dual-target compound had more efficient inhibition at the cellular level. As the results of enzymatic and antitumor activity in cell lines showed that X22 is the best in this class, we performed further in-depth in vitro and in vivo biological studies using this compound.

Molecular docking studies were carried out to investigate the binding modes of compound X22. X22 is a potent CDK4 and CDK9 inhibitor with IC50 value of 30 and 10 nM, respectively, and also has weak inhibition activity against CDK6 with IC50 value of 126 nM. As shown in Figure 1(A), X22 binds to the ATP-binding sites of CDK6 with two key hydrogen bonds formed by aminopyrimidine and the backbone VAL101 residue, which retained the binding mode of the scaffold of ribociclib and CDK6 as reported. Given no 3D CDK4-ligand was reported, the structure of CDK6-ligand complex (PDB code: 4EZ5) was used as a template for homology modelling to generate the 3D structure of CDK4-ligand (Figure 1(B)). Importantly, two additional hydrogen bonds were formed because of the hydrophobic side chain containing isothiocyanate. The sulphur atom formed two hydrogen bonds with the backbone of ALA16 and TYR17 at the front of the ATP binding site of CDK4, respectively, which might explain the better inhibitory activity of the compound X22 against CDK4 (IC50 = 30 nM) than CDK6 (IC50 = 126 nM). In Figure 1(C), the 2-aminopyrimidine formed two hydrogen bonds with the CYS106 residue of X22 in CDK9 (VAL101 in CDK6, VAL in CDK4). As well, the nitrogen atom formed a key hydrogen-bond with the residue of the LYS151 at the front of the ATP binding pocket. At the back of the ATP binding site, the pyrrrolo-[2,3-d]-pyrimidine scaffold exploited the hydrophobic region close to the gatekeeper residue to form a favourable π–π interaction in all three kinases region.

Interestingly, a hydrogen-bond was formed between the oxygen of the sulphonyl of X22 with the backbone of the ASP109 in another docking configuration (Figure 2(A)). At the front of the ATP binding pocket in CDK9, GLY112 possessing the smallest residue makes this hydrophobic site accommodate flexible side chain like compound X22, while THR107 at the same position in CDK6 shows a little crowded for flexible group (Figure 2(B)). The much bigger hydrophobic site permit the compound X22 exits in multiple configurations docking CDK9 forming hydrogen bond for binding tightly. The difference might offer an explanation the stronger inhibitory potency compound X22 against CDK9 (IC50 = 10 nM). Thus, X22 as an ATP-competitive inhibitor potently binds in the ATP pockets of CDKs kinases.

Given the strong inhibitory ability of X22 in MCF7 and A549 cells, we examined the effect of X22 on the cell cycle. Cells were treated with compound X22, ribociclib and DMSO for 24 h. Representative flow cytometry patterns are shown in Figure 3. The results showed that X22 significantly blocked the cell cycle at G2/M phase in a dose-dependent manner accompanied by decreases in S phase in both cell lines, as compared to the cells incubated with DMSO. Ribociclib mainly blocked the cell cycle at G1 phase (Figure 3). We also detected cell kinetics treated with X22, ribociclib and DMSO for 12, 36 and 48 h (Supplementary Figure S3). These results confirmed that X22 induced the cell cycle arrest, which are consistent with our observations above. Compared with CDK4 depletion alone, combined depletion CDK4 and CDK9 induced substantial G2/M arrest. These data indicated that X22 could induce G2/M phase arrest of the cell cycle in both breast and lung cancer cells.

As reported, CDK4/6 preferentially bind D-type cyclins to form complexes. Activations of these complexes are responsible for the phosphorylation of retinoblastoma protein (Rb), which
allows cell cycle to proceed from G1 to S phase and further results in cell proliferation. In contrast, CDK9 is not a typical Cdc-2-like kinase and does not participate in cell cycle regulation. It can form the P-TEFb complex, which is capable of phosphorylating the CTD of the largest subunit of RNAPII and regulate the RNA transcription elongation.

To further verify the inhibitory effect of compound X22 on CDKs, western blotting analysis was performed. We found that X22 treatment significantly suppressed the phosphorylation of Rb at CDK4/6 specific site Ser 780 and CDK9 specific sites Ser 807/811 in MCF7 and A549 cells respectively, which confirmed that X22 targeted on CDKs (Figure 4). We also detected the level of phosphorylated Ser2 (Ser2-P), a well-established cellular target of CDK9 on the RNAPII CTD during transcription elongation. Compared to cells treated with DMSO, X22 effectively inhibited the phosphorylation of Ser2 and Ser5 at 0.5 μM in MCF7 cells and 1 μM in A549 cells (Figure 4). Taken together, the results above revealed that X22 could specifically target CDKs, thus further regulating their downstream signalling proteins in cancer cells.

We next analysed whether X22 treatment promoted cell apoptosis by Annexin V-FITC/PI staining. After 48 h incubation, X22 dose-dependently increased the proportion of apoptotic cells (Q2 late apoptotic and Q3 early apoptotic) in A549 cells, compared to the cells treated with DMSO or ribociclib. Similar results were also observed in MCF7 cells. X22 at 0.1 to 0.5 μM increased the percentages of apoptotic cells by approximately 2.2 to 3.5-fold change, compared to DMSO-treated cells (Figure 5(A)). To further confirm the apoptosis induction of compound X22, we examined the expression of relevant proteins by Western blot. Cells were treated with or without compound X22 and control for 48 h and then lysed and analysed. Given the crucial role of p53 in regulating cell apoptosis, we detected whether compound X22 induced apoptosis depending on the expression of p53 and its downstream targets. As illustrated in Figure 5(B), X22 treatment remarkably increased the expressions of p53 and promoted the phosphorylation of p53 at Ser15. We also demonstrated that X22-induced apoptosis in solid tumour cells, which reduced expression of the anti-apoptotic protein Bcl-2 and enhanced expression of Bax.
Figure 4. X22 suppressed the downstream signalling proteins of CDK4/6 in breast and lung cancer cells. Cells were incubated with the indicated concentrations of X22 or ribociclib for 24 h. Proteins were extracted and analysed by western blotting.

Figure 5. X22 induced cell apoptosis in breast and lung cancer cells. (A) Cells were seeded in six-well plates and treated with the indicated concentrations of X22 or ribociclib for 48 h. Cells were then stained with the AnnexinV-FITC Apoptosis Detection Kit, followed by flow cytometry analysis. Quantitative data are expressed as mean ± SD of the percentages of apoptotic cells from three independent experiments. (B) Expressions of p53, phospho-p53 (Ser15), Bax, Bcl-2 in MCF-7 and A549 cells were detected by western blotting after the treatment with the indicated concentrations of ribociclib or X22 for 48 h. *p < 0.05 versus DMSO; **p < 0.01 versus DMSO; ***p < 0.001 versus DMSO.
These findings indicated that compound $X22$-induced apoptosis is associated with upregulating pro-apoptotic protein p53 and Bax and downregulating anti-apoptotic protein Bcl-2 expression. Collectively, $X22$ may induce cell apoptosis through p53/Bax/Bcl-2 pathway in breast and lung cancer cells.

To better assess whether $X22$ could efficiently suppress tumour growth in vivo, homograft tumour models were established using 4T1 cells. Oral treatment with $X22$ significantly suppressed the tumour growth (Figure 6(A)). Representative photographs of excised tumours at day 18 were shown in Figure 6(B). $X22$ treatment with 15 or 30 or 60 mg/kg substantially inhibited the tumour growth with tumour inhibition rates of 51.8 ± 17.5%, 65.4 ± 11.7% and 70.3 ± 4.4%, respectively. In contrast, tumour volume in ribociclib-treated group decreased slightly compared with vehicle group. Tumour growth inhibitions of 17.2 ± 5.2% were observed at doses of 60 mg/kg of ribociclib. The potencies of ribociclib are relatively weaker than those of $X22$. The average tumour weight of excised tumours in $X22$ groups was obviously lighter than those in other groups (Figure 6(C)). A preliminary toxicity evaluation for $X22$ was also carried out. Mouse weights were monitored twice per week over 18 days. There was no significant difference among the five groups of mice (Figure 6(D)). No obvious signs of toxicity were observed in the $X22$-treated groups, indicating that compound $X22$ is well tolerated in vivo.

4. Conclusions

To date, selective CDK inhibitors have produced only modest activity against solid tumours. In this article, we discovered and studied the medicinal chemistry of multi-CDKs inhibitors to assess their relative activities against the cell cycle and transcriptional CDKs. Several compounds inhibited CDK4 and CDK9 at low nanomolar levels and exhibited good antiproliferative activities in a panel of tumour cells. The most potent analogue $X22$ potently inhibited CDK4 and CDK9 with $IC_{50}$ values of 30 and 10 nM, respectively, which showed marked antitumor activity. In vitro cellular assays, $X22$ was capable of blocking the cell cycle at G2/M phase resulting in decreased S-phase populations. Compared with CDK4 depletion alone, combined depletion induced apoptosis in cancer cells in a dose-dependent manner. Western blot assays confirmed substantial apoptosis after $X22$-induced CDK4 and CDK9 depletion. Meanwhile, $X22$ reduced RNA polymerase II expression and CTD phosphorylation. In in vivo assay, oral administration of compound $X22$ once-daily at 15, 30 or 60 mg/kg for 18 days led to tumour regression without obvious toxicity. Thus, reduced CDK4 activity in concert with depleted CDK9 activity may enhance the antiproliferative effects. This study suggest combined depletion of cell cycle and transcriptional CDK activities may be worthy of clinical further development for solid tumour therapy.

Disclosure statement

The authors report no declarations of interest.

Funding

This work was supported by the National Key Research and Development Programme of China (2018YFE0114300) and the National Natural Science Foundation of China (81972882 and 81903099).

References

1. Ciceri P, Muller S, O’Mahony A, et al. Dual kinase-bromodomain inhibitors for rationally designed polypharmacology. Nat Chem Biol 2014;10:305–12.
2. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011;144:646–74.
3. Johnson LN, Lewis RJ. Structural basis for control by phosphorylation. Chem Rev 2001;101:2209–42.
4. Adams JA. Kinetic and catalytic mechanisms of protein kinases. Chem Rev 2001;101:2271–90.
5. Huang M, Shen AJ, Ding J, Geng MY. Molecularly targeted cancer therapy: some lessons from the past decade. Trends Pharmacol Sci 2014;35:41–50.
6. Ma WW, Adjei AA. Novel agents on the horizon for cancer therapy. Ca Cancer J Clin 2009;59:111–37.
7. Sun C, Bernards R. Feedback and redundancy in receptor tyrosine kinase signaling: relevance to cancer therapies. Trends Biochem Sci 2014;39:465–74.
8. Wu P, Nielsen TE, Clausen MH. FDA-approved small-molecule kinase inhibitors. Trends Pharmacol Sci 2015;36:422–39.
9. Baker SJ, Reddy EP. Targeted inhibition of kinases in cancer therapy. Mt Sinai J Med 2010;77:573–86.
10. Krug M, Hilgeroth A. Recent advances in the development of multi-kinase inhibitors. Mini Rev Med Chem 2008;8:1312–27.
11. Asghar U, Witkiewicz AK, Turner NC, et al. The history and future of targeting cyclin-dependent kinases in cancer therapy. Nat Rev Drug Discov 2015;14:130–46.
12. Peyressatre M, Prevel C, Pellerano M, Morris MC. Targeting cyclin-dependent kinases in human cancers: from small molecules to peptide inhibitors. Cancers 2015;7:179–237.
13. Deshpande A, Sicinski P, Hinds PW. Cyclins and cdks in development and cancer: a perspective. Oncogene 2005;24:2909–15.
14. Kalra S, Joshi G, Munshi A, Kumar R. Structural insights of cyclin dependent kinases: Implications in design of selective inhibitors. Eur J Med Chem 2017;142:424–58.
15. Harbour JW, Luo RX, Dei Santi A, et al. Cdk phosphorylation triggers sequential intramolecular interactions that progressively block Rb functions as cells move through G1. Cell 1999;98:859–69.
16. Romano G. Deregulation in the cyclin-dependent kinase-9-related pathway in cancer: implications for drug discovery and development. ISRN Oncol 2013;2013:1–14.
17. Morales F, Giordano A. Overview of CDK9 as a target in cancer research. Cell Cycle 2016;15:519–27.
18. Wang S, Fischer PM. Cyclin-dependent kinase 9: a key transcriptional regulator and potential drug target in oncology, virology and cardiology. Trends Pharmacol Sci 2008;29:302–13.
19. Bose P, Simmons GL, Grant S. Cyclin-dependent kinase inhibitor therapy for hematologic malignancies. Expert Opin Investig Drugs 2013;22:723–38.
20. Vijayaraghavan S, Moulder S, Keyomarsi K, et al. Inhibiting CDK in cancer therapy: current evidence and future directions. Targeted Oncol 2018;13:21–38.
21. Sarosiek T. Inhibitors of cyclin-dependent kinases (CDK) – a new group of medicines in therapy of advanced breast cancer. Polski Merkuriusz Lekarski: organ Polskiego Towarzystwa Lekarskiego 2018;44:5–9.
22. Heptinstall AB, Adiyasa I, Cano C, Hardcastle IR. Recent advances in CDK inhibitors for cancer therapy. Future Med Chem 2018;10:1369–88.
23. Shapiro GI. Cyclin-dependent kinase pathways as targets for cancer treatment. J Clin Oncol 2006;24:1770–83.